Revenue (Details) - USD ($) $ in Thousands	3 Months Ended
Revenue (Details) - USD ($) $ in Thousands	Mar. 30, 2025	Mar. 31, 2024	Dec. 29, 2024
Disaggregation of Revenue [Line Items]
Segment revenue	$ 664,762	$ 649,920
Unbilled Receivables	80,400		$ 80,600
Deferred Revenue	223,100		212,800
Customer Deposits in Advance of Transfer of Control, Current	$ 19,600		$ 19,500
Remaining Performance Obligations	Transaction price allocated to the remaining performance obligationsThe Company applies the practical expedient and does not disclose information about remaining performance obligations that have original expected durations of one year or less. The estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the end of the period are not material to the Company. The remaining performance obligations primarily include noncancelable purchase orders, noncancelable software subscriptions and cloud service contracts and long-term prepaid storage contracts.
Contract with Customer, Asset and Liability [Abstract]
Contract with Customer, Asset, Net, Current - Not Material	The Company had no material contract assets as of March 30, 2025 and December 29, 2024.
Americas [Member]
Disaggregation of Revenue [Line Items]
Segment revenue	$ 304,629	294,354
Europe [Member]
Disaggregation of Revenue [Line Items]
Segment revenue	181,792	178,562
Asia [Member]
Disaggregation of Revenue [Line Items]
Segment revenue	178,341	177,004
Diagnostics [Member]
Disaggregation of Revenue [Line Items]
Segment revenue	324,367	313,406
Diagnostics [Member] \| Americas [Member]
Disaggregation of Revenue [Line Items]
Segment revenue	120,350	117,777
Diagnostics [Member] \| Europe [Member]
Disaggregation of Revenue [Line Items]
Segment revenue	105,770	101,106
Diagnostics [Member] \| Asia [Member]
Disaggregation of Revenue [Line Items]
Segment revenue	98,247	94,523
Life Sciences [Member]
Disaggregation of Revenue [Line Items]
Segment revenue	340,395	336,514
Life Sciences [Member] \| Americas [Member]
Disaggregation of Revenue [Line Items]
Segment revenue	184,279	176,577
Life Sciences [Member] \| Europe [Member]
Disaggregation of Revenue [Line Items]
Segment revenue	76,022	77,456
Life Sciences [Member] \| Asia [Member]
Disaggregation of Revenue [Line Items]
Segment revenue	80,094	82,481
Life Sciences Solutions [Member]
Disaggregation of Revenue [Line Items]
Segment revenue	286,453	291,612
Life Sciences Solutions [Member] \| Diagnostics [Member]
Disaggregation of Revenue [Line Items]
Segment revenue	0	0
Life Sciences Solutions [Member] \| Life Sciences [Member]
Disaggregation of Revenue [Line Items]
Segment revenue	286,453	291,612
Software [Member]
Disaggregation of Revenue [Line Items]
Segment revenue	53,942	44,902
Software [Member] \| Diagnostics [Member]
Disaggregation of Revenue [Line Items]
Segment revenue	0	0
Software [Member] \| Life Sciences [Member]
Disaggregation of Revenue [Line Items]
Segment revenue	53,942	44,902
Reproductive health [Member]
Disaggregation of Revenue [Line Items]
Segment revenue	126,805	124,745
Reproductive health [Member] \| Diagnostics [Member]
Disaggregation of Revenue [Line Items]
Segment revenue	126,805	124,745
Reproductive health [Member] \| Life Sciences [Member]
Disaggregation of Revenue [Line Items]
Segment revenue	0	0
Applied genomics [Member]
Disaggregation of Revenue [Line Items]
Segment revenue		649,920
Immunodiagnostics [Member]
Disaggregation of Revenue [Line Items]
Segment revenue	197,562	188,661
Immunodiagnostics [Member] \| Diagnostics [Member]
Disaggregation of Revenue [Line Items]
Segment revenue	197,562	188,661
Immunodiagnostics [Member] \| Life Sciences [Member]
Disaggregation of Revenue [Line Items]
Segment revenue	$ 0	$ 0

REVVITY, INC. 10-Q